文献速递浆细胞疾病

新诊断多发性骨髓瘤中达平台期时间对生存的预测作用

Time to plateau as a predictor of survival in newly diagnosed multiple myeloma.
PubMed 文献 · Am J Hematol · 2018-01-01

该研究纳入2005至2015年在本中心接受新型药物治疗的1099例新诊断多发性骨髓瘤患者,分析达平台期时间(TPlat)与生存的关系。中位TPlat为4.9个月(0.7-58.6),平台期持续时间为1.8年(0.2-11.0)。TPlat>120天的患者从最佳缓解界标算起的改良总生存(mOS)和无进展生存(mPFS)均更长(P均<.001)。

要点

  • 中位TPlat为4.9个月(范围0.7-58.6),中位平台期持续时间为1.8年(范围0.2-11.0)。
  • TPlat>120天的患者mOS和mPFS更长,从最佳缓解界标算起P均<.001。
  • 按年龄和是否接受 upfront ASCT 分层的亚组分析中,mOS改善均保持(P均<.001)。

核心结论

  • 作者认为对初始治疗反应较缓慢(TPlat>120天)的患者生存期更长。
  • 作者提出TPlat延长可能代表一种「持续应答者」表型,其生存优势独立于 upfront ASCT、缓解深度以及 ISS 分期和细胞遗传学风险等生物学标志。

研究设计与样本

  • 单中心研究,纳入2005至2015年在本中心接受新型药物治疗的1099例新诊断多发性骨髓瘤患者。
  • TPlat定义为从启动一线治疗至一线治疗最佳缓解的时间。

主要发现

  • 中位TPlat为4.9个月(0.7-58.6),平台期持续时间为1.8年(0.2-11.0)。
  • TPlat>120天的患者从最佳缓解界标算起的mOS和mPFS更长(P均<.001)。
  • 按年龄和是否接受 upfront ASCT 分层的亚组分析中,mOS的统计学显著改善均保持(P均<.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Response rates in newly diagnosed multiple myeloma have improved dramatically with the introduction of highly effective novel therapies. However, survival in patients achieving optimal responses to initial treatment can vary significantly, and new prognostic indicators are required to improve risk stratification. We investigated the relationship between time to plateau (TPlat ) and survival in 1099 newly diagnosed patients treated with novel agents at our institution from 2005 to 2015. TPlat was defined as time from initiation of first-line therapy to best response to first-line therapy. The median TPlat was 4.9 months (0.7-58.6) and plateau duration was 1.8 years (0.2-11.0). Patients who required > 120 days to achieve a plateau had longer modified overall survival (mOS) and progression free survival (mPFS) calculated from a landmark of best response (P < .001 for both comparisons). Statistically significant improvement in mOS was retained in subgroup analysis based on age and whether patients received upfront autologous hematopoietic stem cell transplantation (ASCT) (P < .001 for all comparisons). Our results suggest that patients who respond more gradually to initial therapy (TPlat > 120 days) experience longer survival compared to more rapid responders. Patients with a prolonged TPlat could represent an "ongoing responder" phenotype that portends a survival advantage independent of treatment with upfront ASCT, depth of response, and biologic markers such as ISS stage and cytogenetic risk.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Mellors PW, Binder M, Buadi FK, et al. Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. Am J Hematol. 2018. PMID: 29659048. doi:10.1002/ajh.25113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。